Dosage Forms & Drug Delivery Systems – Page 4

Content Uniformity Oos during FDA inspection readiness: GMP investigation steps and batch disposition

The first step in addressing an OOS issue related to content uniformity involves identifying symptoms or signals that indicate a problem. Common signals might include:Click to read the full article.

Capsule Fill Weight Variation during FDA inspection readiness: sampling plan fixes to avoid repeat OOS

Recognizing the symptoms of fill weight variation is the first step in an effective investigation. Symptoms may manifest as OOS results during routine testing, with weights falling outside the established…

Tablet Capping during high-speed runs: GMP investigation steps and batch disposition

Symptoms associated with tablet capping typically manifest during the compression process or afterward, significantly affecting production yields and product quality. Some identifiable signals include:Click to read the full article.

Blend Segregation after excipient change: how to document to meet FDA/EMA expectations

Identifying the symptoms of blend segregation is the first step toward effective investigation. Typical signals include:Click to read the full article.

Hardness Drift after excipient change: process parameter limits and validation impacts

Symptoms of hardness drift can be observed at various stages of the manufacturing process, often manifesting before extensive testing. The following signals may indicate a potential hardness issue:Click to read…

Tablet Lamination during FDA inspection readiness: how to document to meet FDA/EMA expectations

Symptoms indicating issues during tablet lamination may arise from both the manufacturing floor and laboratory settings. Common signals include:Click to read the full article.

Blend Segregation after excipient change: GMP investigation steps and batch disposition

Steps to Investigate Blend Segregation Following an Excipient Change in Pharmaceuticals In pharmaceutical manufacturing, the integrity of blended materials is crucial for ensuring product quality. Blend segregation following an excipient…

Capsule Fill Weight Variation during FDA inspection readiness: tooling, granulation, and lubrication troubleshooting

Recognizing symptoms and signals early in the production process is crucial for effective investigation. Key indicators of capsule fill weight variation may include:Click to read the full article.

Content Uniformity Oos post-stability pull: GMP investigation steps and batch disposition

Signs of potential issues with content uniformity can originate from multiple sources. Here are several indicators that should trigger immediate investigation:Click to read the full article.

Blend Segregation after scale-up: process parameter limits and validation impacts

Understanding the early indications of blend segregation is crucial for timely intervention. Common symptoms associated with blend segregation include:Click to read the full article.

Tablet Capping during FDA inspection readiness: root cause analysis with CAPA evidence pack

The first step in addressing tablet capping is recognizing the signs indicative of this failure. Symptoms may manifest in various forms:Click to read the full article.

Disintegration Failure in multi-strength campaign: sampling plan fixes to avoid repeat OOS

The first step in addressing disintegration failures is to identify indicative symptoms that manifest during manufacturing or quality control activities. These include:Click to read the full article.